Consideration will be given to:
• Extent to which the product delivers value through improved diagnosis, prevention, treatment, mitigation and/or management of chronic and acute conditions for the benefit of the patient.

Demonstrated understanding of the end user(s) and how they will interact with the product, including:
• Description of how the solution fits within clinical workflows and/or typical patient journeys.  
• Differentiation between the user(s), payers and beneficiaries  
• Evidence of Voice of User.

Uniqueness:
• Clear articulation of competitive position and product advantage.

Maturity of the technology, including:
• Technical: evidence of proof of principle/concept use in the clinical or market setting is detailed; where applicable, access rights to key data required for operation are outlined (e.g. AI/ML training data).
• Strategy for patient data privacy and security.  
• Clinical: level of product evidence including clinical trials and technical certification.
• Regulatory: consideration of regulatory strategy including identification of TGA regulatory classification.  
• Traction: use of the product in a clinical or market setting.
• Scalability: consideration of barriers to scalability, such as required integrations, and extent of stakeholder identification and engagement.

Market and business case, including:
• Feasible business model.
• Articulation of value proposition to identified payers.  
• Evidence of market appetite, including Voice of Paying Customer evidence.  
• Size of market and pathway to market.  
• Intellectual property strategy and position.  
• Barriers to market entry.

Team, including:
• Business skills.
• Technical skills.  
• Track record and ability to achieve market uptake.  
• Diversity and inclusion: evident diversity in the advisory board, board, management team and a feasible strategy for maintaining/ achieving diversity.

Proposed Projects:
•Extent to which the proposed projects will positively affect clinical and commercial readiness of the project.

Preference will be given to companies who can demonstrate significant understanding of the complexity of the challenges of commercialisation of digital health.

All applications must be lodged through the online platform Gust, accessible here.

Before lodging your application, follow the steps below:
‍
1. Interested applicants should register for an information session here.
‍
2. Once eligibility is confirmed and you have read the information on the website and attended the information session, applicants are encouraged to book a pre-application consultation appointment here with an ANDHealth team member to discuss your proposed application and specific questions via the ANDHealth website, this will be released after the information session.
‍
3. The application consists of application questions, a proposed project outline, and upload of four attachments:
‍
   • Investor Pitch deck
   • ANDHealth Lean Canvas
   • 3-5 Year Financial Model
   • Letter of Board support (in the event that the applicant does not have a board, an option will       be made available for a letter from the CEO)
   • All applicants must articulate two projects (see ANDHealth+ Types of Projects tab) for which participation in the program will improve the likelihood of securing investment and/or substantially progress market entry.

4. To submit the application, applicants must also read and agree to the cohort company expectations document which is found on Gust.

5. Applications are assessed by the highly experienced ANDHealth team and ANDHealth Industry Selection Panel.

6. Top 10 applicants will undertake a 60 minute presentation and interview with the Industry Selection Panel.
‍
7. The International Investment Advisory Committee (IIAC) will review and ratify the Industry Selection Panel’s recommendations for successful applicants.

8. Successful applicants will be notified. All unsuccessful applicants are provided with written feedback specific to their application.
‍

Proposed Projects should focus on the development of clinical and/or commercial evidence to significantly improve the project’s ability to commercialise, raise growth capital and/or execute on a market entry or growth strategy.  

‍Two sequential projects will be supported with relevant milestones and go-no points defined within each.

Stage 1 (duration 3-4 months): 
‍Activities will focus on identifying key risks through a ‘working backwards’ model and, where possible, addressing them using third party expertise and the expertise of each company’s IAP. Outcomes of Stage 1 activities and the Stage 1 Investor & Customer Deal Flow Days will be used to inform Stage 2 project activities. 
‍
Stage 2 (duration 8-10 months):
Activities will focus on achieving key clinical and commercial milestones which will drive institutional investment and/or enterprise customer uptake. Project activities will be focused on significant pieces of work which will have a clear and demonstrable impact on the growth trajectory of each cohort company.  
‍
‍Note: Stage 2 projects will be subject to review by the IIAC and it is expected that some companies may not progress to stage 2.
‍
‍Eligible activities include but are not limited to:

Product Development
• Product Verification and Validation  
•End-User Studies 
•UX/UI development to drive improved clinical outcomes 
• Intellectual property strategy 
‍
Clinical Developments and Outcomes 
• Clinical Trial Planning and Protocol Design 
• Clinical Trial/Study Design and Execution 
• Clinical Trial Data Analytics 
• Efficacy in a clinical or industry setting 
• Voice of End-user(s) in clinical settings 
 
Manufacturing 
• Manufacturing assessments  
• Designfor Manufacture 
• Scaleup Manufacturing plans 
‍
Commercial Strategy, Evidence and Outcomes 
• Go-to-Market Planning 
• Voice of Paying Customer Studies 
• Commercial Pilot Programs 
• Health Economics Assessments 
• Business Validation in End User Settings  
• International Market Strategy 
• Health Data and Independent Market Intelligence  
• Business and Financial Modelling 

Regulatory and Reimbursement  
• Independent Regulatory Strategy and Audits 
• Regulatory Certification or roadmap to certification (eg,TGA, FDA) 
• Reimbursement and Pricing Strategy, Verification and Audits 
• Cybersecurity  
• Data collection, storage, security and privacy  
• Quality Management Systems planning 
• Multi-jurisdictional compliance planning    

‍Ineligible activities include expenses not directly related to the projects approved within the ANDHealth+program. ‘Business as usual’ operations will not be supported. 

Ineligible activities include (but are not limited to): 
‍
• General and administration costs for day-to-day business expenditure 
• Non-related staffing or contracting costs including the time commitment of applicant’s staff to supporting project activities 
• Ongoing software and hardware development 
• Marketing and branding costs 
• Fees paid to incentivise customers to use/ purchase your product or services  
• Costs of non-project specific travel and associated quarantine/ medical costs 
• Fees to government agencies such as ASIC.   

‍This is not a grant program. Project funds approved by the ADHAF are managed and paid directly to third-party suppliers by ANDHealth on behalf of successful applicants where possible. In certain situations, project funds may be paid to participating companies directly for expenditure on agreed outcomes. Participating companies will be required to provide verification of expenditure upon request by ANDHealth.  

‍Please note: Third-party activities supported by ANDHealth+ and financed by the ADHAF are carried out via a competitive tender. The tender process and contracting are supported by the applicant’s ANDHealth project support team. Within the application, applicants should focus on outlining the proposed activities and targeted outcomes, rather than including specific proposals from third-party providers.   

ANDHealth may determine that expenditure is ineligible and not directly related to the specific project at its discretion.